A

AnaptysBio

D
ANAB
USD
-0.695
(-3.1292%)
Market Closed
19,727.00
Volume
-6.505
EPS
-
Div Yield
-3.388189
P/E
649,748,998.21
Market Cap
Today
-3.1292%
1 Week
-0.715%
1 Month
-34.823%
6 Months
-16.023%
12 Months
30.157%
Year To Date
0.444%
All Time
0%

Title:
AnaptysBio

Sector:
Healthcare
Industry:
Biotechnology
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA)and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Do you need help or have a question?